Electronic Reminders Keep TB Patients on Track With Medication In China
News Sep 22, 2015
Researchers from the London School of Hygiene & Tropical Medicine and the National Center for Tuberculosis Control and Prevention in China conducted a trial with 4,173 patients from the provinces of Heilongjiang, Jiangsu, Hunan, and Chongqing. Patients either received text message reminders, an electronic medication monitor, both, or no reminders for their six month treatment period.
Patients receiving no reminders missed taking 29.9% of their medication doses and patients receiving text messages missed 27.3% of their doses. However, patients with an electronic medication monitor box – which beeped if not opened at the agreed time – only missed 17% of their medication doses. Patients who received both text messages and an electronic medication monitor missed just 13.9% of medication doses.
According to the World Health Organization, China has the world’s second largest number of TB cases, accounting for 11% of the estimated 9 million global cases.
TB treatment usually lasts for six months and is effective if taken fully, but patients missing drug treatment doses is a major problem. This increases the risk of having a relapse of TB and also TB becoming drug resistant, making the disease more difficult to treat and potentially fatal.
Senior author Dr Katherine Fielding of the London School of Hygiene & Tropical Medicine, said: “Global plans to reduce TB advise that treatment be taken under the direct observation of a healthcare worker to reduce missed doses, something which has been difficult to carry out in many parts of China, particularly in rural areas, as in other parts of world. Innovative approaches are needed to tackle this problem.
“Our study is the first large-scale randomised trial to carefully evaluate whether electronic reminders can help patents to take their tuberculosis treatment on their own. Our findings show real promise. A low-cost, reliable electronic medication monitor could improve TB treatment for thousands of people across China.”
Project investigator Dr Shiwen Jiang of the National Center for Tuberculosis Control and Prevention, added: “Directly observed therapy is difficult to implement in China due to limited human resources, poor acceptance and other factors. Our study aimed to assess whether the use of the medication monitor and/or text messaging can improve adherence to TB drugs. Our results are encouraging. We are currently planning a further evaluation of a management model including the use the medication monitor on long-term TB outcomes including TB recurrence. China plans to scale up the use of medication monitors in some provinces in the next five years.”
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE